For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 2,000 | 2,500 |
| Research and development | 469,000 | 185,000 | 347,000 | 90,500 |
| General and administrative | 718,000 | 854,000 | 747,000 | 1,115,000 |
| Total operating expenses | 1,187,000 | 1,039,000 | 1,094,000 | 1,205,500 |
| Loss from operations | -1,187,000 | -1,039,000 | -1,092,000 | -1,203,000 |
| Change in fair value of warrant liability | 0 | 31,000 | - | - |
| Other income, net | 28,000 | 19,000 | 19,000 | 33,250 |
| Other income (expense), net | 28,000 | -12,000 | 19,000 | 33,250 |
| Net loss | -1,159,000 | -1,051,000 | -1,073,000 | -1,169,750 |
| Earnings per share, basic, total | -0.55 | -0.63 | -0.67 | -0.73 |
| Earnings per share, diluted, total | -0.55 | -0.63 | -0.67 | -0.73 |
| Weighted average number of shares outstanding, basic, total | 2,183,039 | 1,676,345 | 1,601,252 | 400,313 |
| Weighted average number of shares outstanding, diluted, total | 2,183,039 | 1,676,345 | 1,601,252 | 400,313 |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)